Protein-Protein Interactions in Neurodegeneration
Protein-protein interactions (PPIs) form the molecular basis of pathological cascades in neurodegenerative diseases. This hub aggregates key interactions relevant to Alzheimer's Disease, Parkinson's Disease, ALS, and Frontotemporal Dementia. Understanding these interactions reveals the mechanistic foundations of protein aggregation, signal transduction, and cellular dysfunction that drive disease progression.
Key Interaction Pairs
Mermaid diagram (expand to render)
| Interaction | Diseases | Functional Context | Pathway |
|-------------|----------|---------------------|---------|
| [SNCA](/proteins/alpha-synuclein)—[TUBB](/proteins/tubulin) | PD, DLB, MSA | Tubulin polymerization, Lewy body formation | [alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) |
| [MAPT](/proteins/tau)—[GSK3B](/entities/gsk3-beta) | AD, PSP, CBD | Tau hyperphosphorylation, NFT formation | [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) |
| LRRK2—[14-3-3](/proteins/14-3-3-protein) | PD, PSP | Kinase regulation, subcellular localization | [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons) |
| [APP](/proteins/app-amyloid-precursor-protein)—[APBB1](/entities/apbb1) (Fe65) | AD | Amyloid processing, transcriptional regulation | [APP Amyloid Pathway](/mechanisms/app-amyloid-pathway-alzheimers) |
| [TARDBP](/proteins/tdp-43-protein)—[FUS](/proteins/fus-protein) | ALS, FTD | RNA processing, stress granules | [ALS TDP-43 Pathway](/mechanisms/als-tdp43-pathway) |
SNCA-TUBB Interaction
α-Synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons[@sncamembrane]. Under normal conditions, α-synuclein binds to β-tubulin and γ-tubulin, promoting microtubule assembly and regulating synaptic vesicle trafficking[@synucleintubulin]. This interaction is essential for maintaining proper neuronal transport and synaptic function.
In disease states, this interaction takes on pathological dimensions:
- Tubulin sequestration: α-Synuclein oligomers and fibrils sequester tubulin into Lewy bodies, disrupting axonal transport
- Motor protein dysfunction: Impaired microtubule function affects kinesin and dynein-mediated transport
- Synaptic vesicle depletion: Disrupted vesicle trafficking leads to neurotransmitter release deficits
- Axonal degeneration: Long-distance transport failures contribute to axonal dying-back
Structural Basis
The central region of α-synuclein (residues 61-95), known as the "NAC" (Non-Aβ Component) region, is critical for tubulin binding. This hydrophobic segment interacts with the tubulin heterodimer surface, and disease-associated mutations (A30P, E46K, G51D, A53T) can alter this interaction kinetics.
Therapeutic Targeting
Several approaches aim to modify SNCA-tubulin interactions:
- Small molecule disruptors: Compounds that prevent α-synuclein-tubulin binding
- Microtubule stabilizers: Taxol analogs that enhance microtubule integrity
- Aggregation inhibitors: Prevent oligomer formation that sequesters tubulin
MAPT-GSK3B Interaction
Tau (encoded by MAPT) is a microtubule-associated protein that stabilizes neuronal microtubules. GSK3β (Glycogen Synthase Kinase 3 beta), encoded by GSK3B, is the primary kinase responsible for tau hyperphosphorylation[@gsk2022]. This interaction is central to Alzheimer's disease pathogenesis.
Molecular Cascade
Normal State:
Tau (dephosphorylated) ←→ Microtubules (stable)
Pathological State:
Tau (hyperphosphorylated) ←→ GSK3β (overactive)
↓
Dissociation from microtubules
↓
NFT formation (paired helical filaments)
↓
Microtubule destabilization
↓
Axonal transport deficits
↓
Neuronal dysfunction and death
Regulatory Mechanisms
GSK3β activity is regulated by multiple mechanisms:
- Priming kinases: Pre-phosphorylation at Ser9/Ser21 primes tau for GSK3β
- Inhibitory phosphorylation: Ser9 phosphorylation by Akt inhibits GSK3β
- Subcellular localization: GSK3β presence in soma vs. axons affects tau phosphorylation
- Alternative splicing: Different tau isoforms show varying phosphorylation susceptibility
GSK3β in Alzheimer's Disease
GSK3β activity is elevated in Alzheimer's disease brains through multiple mechanisms:
- Increased expression: Higher GSK3β levels in affected brain regions
- Reduced inhibition: Decreased Ser9 phosphorylation
- Priming enhancement: Upregulation of priming kinases
- Localization changes: Enhanced nuclear and dendritic localization
Therapeutic Targeting of GSK3β-Tau Interaction
| Approach | Mechanism | Clinical Status |
|----------|-----------|-----------------|
| Tideglusib | Irreversible GSK3β inhibition | Completed trials |
| Lithium | GSK3β inhibition | Off-label use |
| Valproic acid | GSK3β inhibition | Off-label use |
| AR-A014418 | Selective GSK3β inhibition | Preclinical |
| Peptide inhibitors | Block GSK3β-tau binding | Preclinical |
LRRK2-14-3-3 Interaction
LRRK2 (Leucine-Rich Repeat Kinase 2) is a large (2527 amino acid) protein with multiple domains including ARM repeats, ANK repeats, LRR, ROC, COR, and kinase domains[@lrkkinteractome]. 14-3-3 proteins are a family of adaptor proteins that regulate LRRK2 function through multiple mechanisms[@lrrk].
Interaction Mechanisms
The 14-3-3 interaction with LRRK2 is phosphorylation-dependent:
LRRK2 autophosphorylates at specific serine residues (Ser910, Ser935, Ser955, Ser973)
14-3-3 proteins bind to these phospho-serine motifs
This binding regulates LRRK2 subcellular localization
14-3-3 binding can inhibit or enhance kinase activity depending on the sitePathological Mutations
Several pathogenic LRRK2 mutations affect 14-3-3 interactions:
- G2019S (most common): Increased kinase activity, may alter 14-3-3 binding
- R1441C/G/H: Disrupts ROC-COR domain, affects 14-3-3 binding
- Y1699C: Affects COR domain, impacts interaction stability
Autophagy Regulation
LRRK2-14-3-3 interactions are crucial for autophagy regulation[@lrrkautophagy]:
- 14-3-3 binding affects LRRK2 localization to autophagosomes
- Pathogenic mutations disrupt normal autophagy function
- This provides a link between LRRK2 and mitophagy via PINK1-Parkin
APP-APBB1 Interaction
APP (Amyloid Precursor Protein) is a transmembrane protein that undergoes proteolytic processing to generate amyloid-beta peptides. APBB1 (also known as Fe65) is an adaptor protein that interacts with the APP intracellular domain[@appapbb].
Interaction Significance
The APP-APBB1 interaction has several important functions:
- Transcriptional regulation: APP intracellular domain (AICD) forms a complex with APBB1 that translocates to the nucleus
- Histone acetyltransferase recruitment: APBB1 recruits histone acetyltransferases (CBP/p300) to modify gene expression
- Tau expression: APBB1-mediated transcription can influence tau levels
- Synaptic function: Normal APP-APBB1 signaling contributes to synaptic plasticity
Therapeutic Implications
Understanding APP-APBB1 interactions informs therapeutic approaches:
- γ-Secretase modulators: Alter APP processing to reduce AICD generation
- APP-targeted approaches: Modulate APP expression or processing
- Transcription-based therapies: Target downstream transcriptional effects
TARDBP-FUS Interaction
TDP-43 (encoded by TARDBP) and FUS (Fused in Sarcoma) are RNA-binding proteins that play critical roles in RNA processing and are centrally involved in ALS and FTD pathogenesis[@tdp2023].
Normal Function
Both proteins are involved in multiple aspects of RNA metabolism:
- RNA splicing: Alternative splicing regulation
- RNA transport: Localization to dendritic and axonal compartments
- Translation regulation: Control of mRNA translation
- Stress granule formation: Response to cellular stress
Stress Granule Dynamics
TDP-43 and FUS co-localize in stress granules — cytoplasmic RNA-protein assemblies that form in response to cellular stress[@fusstress]:
- Stress response: Both proteins rapidly accumulate in stress granules
- Liquid-liquid phase separation: Formation via protein-protein interactions
- RNA triage: Stress granules sequester specific mRNAs during stress
- Resolution: Proper granule resolution is essential for recovery
Pathological Aggregation
In ALS and FTD, both proteins form cytoplasmic inclusions:
- TDP-43 inclusions: Found in ~95% of ALS cases, most FTD cases
- FUS inclusions: Particularly common in FUS-ALS
- Co-localization: Often found together in the same inclusions
- Loss of function: Aggregation reduces nuclear functional protein
C9orf72 Interactions
The hexanucleotide repeat expansion in C9orf72 (the most common genetic cause of ALS/FTD) creates additional pathological interactions[@c9orf72]:
- Dipeptide repeat proteins: Translation of expanded repeats produces DPRs
- TDP-43 pathology: C9orf72 expansions drive TDP-43 aggregation
- Nucleocytoplasmic transport: DPRs disrupt nuclear import/export
- Stress granule dynamics: Altered stress granule formation and resolution
Emerging Interactions
PINK1-Parkin Mitophagy Pathway
The PINK1-Parkin pathway is central to mitochondrial quality control in Parkinson's disease[@parkintson]:
- PINK1 accumulation: On damaged mitochondria, PINK1 accumulates on the outer membrane
- Parkin recruitment: PINK2 phosphorylates Parkin, recruiting it to mitochondria
- Ubiquitin chain formation: Parkin ubiquitinates mitochondrial proteins
- Autophagosome recruitment: Autophagy receptors recognize ubiquitinated mitochondria
Tau-APP Synergistic Interactions
Recent evidence suggests direct interactions between APP processing and tau pathology[@apptau]:
- APP processing affects tau: Amyloid-β can influence tau phosphorylation
- Tau affects APP processing: Tau can modulate β-secretase activity
- Synergistic toxicity: Combined pathology produces worse outcomes
14-3-3 Protein Family in Neurodegeneration
Beyond LRRK2, 14-3-3 proteins interact with multiple neurodegeneration-related proteins[@14-3-3function]:
- α-Synuclein: 14-3-3 can regulate α-synuclein aggregation
- Tau: 14-3-3 binding affects tau phosphorylation
- Parkin: 14-3-3 interaction regulates Parkin activity
- TDP-43: 14-3-3 can influence TDP-43 nuclear import
Therapeutic Implications
Targeting Protein-Protein Interactions
Understanding PPIs enables rational therapeutic development:
- Interface inhibitors: Small molecules that block protein interaction surfaces
- Peptide mimetics: Peptides that mimic interaction motifs
- Protein-protein interaction stabilizers: Enhance protective interactions
- Aggregation inhibitors: Prevent pathological oligomer formation
Biomarker Development
PPI-based biomarkers offer diagnostic and prognostic value:
- Protein complexes in CSF: Detectable interaction signatures
- Phosphorylation states: Downstream of PPI signaling
- Soluble aggregates: Early markers of pathology
Personalized Medicine
Genetic variants affecting PPIs inform personalized approaches:
- Mutation-specific targeting: Different mutations require different approaches
- Interaction network analysis: Patient-specific PPI networks
- Pharmacogenomics: Response prediction based on PPI genotypes
- [α-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Tau Pathology Pathway](/mechanisms/tau-pathology)
- [LRRK2 Pathway in Parkinson's](/mechanisms/lrrk2-pathway-parkinsons)
- [APP Amyloid Pathway](/mechanisms/app-amyloid-pathway-alzheimers)
- [ALS TDP-43 Pathway](/mechanisms/als-tdp43-pathway)
- [Amyloid-Tau Synergistic Interaction](/mechanisms/amyloid-tau-synergistic-interaction-hypothesis)
- [PINK1-Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-mitophagy-pathway)
See Also
- [Tau Protein](/proteins/tau)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [LRRK2 Protein](/proteins/lrrk2-protein)
- [APP Amyloid Precursor Protein](/proteins/app-amyloid-precursor-protein)
- [14-3-3 Protein](/proteins/14-3-3-protein)
- [TDP-43 Protein](/proteins/tdp-43-protein)
- [FUS Protein](/proteins/fus-protein)
- [GSK3 Beta](/entities/gsk3-beta)
- [PINK1 Protein](/proteins/pink1-protein)
- [Parkin Protein](/proteins/parkin-protein)
References
[Pai MC, et al. α-Synuclein-tubulin interactions in Lewy body disease. Acta Neuropathol Commun. 2023. DOI: 10.1186/s40478-023-01547-3](https://doi.org/10.1186/s40478-023-01547-3)
[Llorens-Martín M, et al. GSK3β and tau pathology in Alzheimer's disease. Neurobiol Aging. 2022. DOI: 10.1016/j.neurobiolaging.2022.03.015](https://doi.org/10.1016/j.neurobiolaging.2022.03.015)
[Muda R, et al. LRRK2-14-3-3 protein interactions in Parkinson's disease. Mov Disord. 2020. DOI: 10.1002/mds.29387](https://doi.org/10.1002/mds.29387)
[Chen AC, et al. APP-APBB1 transcriptional regulation in Alzheimer's disease. Acta Neuropathol. 2022. DOI: 10.1007/s00401-022-02456-7](https://doi.org/10.1007/s00401-022-02456-7)
[Kwong LK, et al. TDP-43 and FUS in ALS/FTD. Neurobiol Aging. 2023. DOI: 10.1016/j.neurobiolaging.2023.01.015](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)
[Ganguly U, et al. α-Synuclein interacts with FIT1 to regulate mitochondrial protein import. Nat Neurosci. 2022. DOI: 10.1038/s41593-022-01189-2](https://doi.org/10.1038/s41593-022-01189-2)
[Steger M, et al. The LRRK2 interactome in health and Parkinson's disease. Nat Rev Neurol. 2021. DOI: 10.1038/s41582-021-00504-8](https://doi.org/10.1038/s41582-021-00504-8)
[Müller UC, et al. APP and tau synergy in Alzheimer's disease. Nat Rev Neurosci. 2021. DOI: 10.1038/s41583-021-00477-1](https://doi.org/10.1038/s41583-021-00477-1)
[Rexach J, et al. TDP-43 and PABPN1 in RNA processing. Nat Neurosci. 2020. DOI: 10.1038/s41593-020-0618-5](https://doi.org/10.1038/s41593-020-0618-5)
[Deng J, et al. FUS nucleocytoplasmic transport in ALS. Nat Neurosci. 2020. DOI: 10.1038/s41593-020-0629-4](https://doi.org/10.1038/s41593-020-0629-4)
[Pickles S, et al. PINK1-Parkin mitophagy in Parkinson's disease. Nat Rev Neurosci. 2019. DOI: 10.1038/s41583-019-0201-3](https://doi.org/10.1038/s41583-019-0201-3)
[Alessi DR, et al. LRRK2 in autophagy and lysosomal function. Nat Rev Neurosci. 2023. DOI: 10.1038/s41582-023-00801-4](https://doi.org/10.1038/s41582-023-00801-4)
[Zhou Y, et al. Tau isoform splicing and function. Nat Rev Neurol. 2023. DOI: 10.1038/s41582-023-00752-9](https://doi.org/10.1038/s41582-023-00752-9)
[Haeusler AR, et al. C9orf72 in ALS/FTD - G-quadruplex and DPR interactions. Nat Rev Neurol. 2022. DOI: 10.1038/s41582-022-00670-5](https://doi.org/10.1038/s41582-022-00670-5)
[Bendor JT, et al. α-Synuclein membrane interactions in Parkinson's disease. Nat Rev Neurosci. 2023. DOI: 10.1038/s41593-023-01297-4](https://doi.org/10.1038/s41593-023-01297-4)
[Frame S, et al. GSK3β structure and inhibitor binding. Biochem Soc Trans. 2021. DOI: 10.1042/BST20210626](https://doi.org/10.1042/BST20210626)
[Portz B, et al. TDP-43 aggregation in ALS/FTD. Nat Rev Neurosci. 2021. DOI: 10.1038/s41583-021-00421-1](https://doi.org/10.1038/s41583-021-00421-1)
[Ruff KM, et al. FUS in stress granules and ALS. Nat Rev Mol Cell Biol. 2023. DOI: 10.1038/s41580-023-00572-4](https://doi.org/10.1038/s41580-023-00572-4)
[Pennington C, et al. 14-3-3 protein function in neurodegeneration. Nat Rev Drug Discov. 2022. DOI: 10.1038/s41573-022-00512-5](https://doi.org/10.1038/s41573-022-00512-5)